We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ICER Identifies Most Costly Drug Price Hikes Unsupported by Clinical Evidence
ICER Identifies Most Costly Drug Price Hikes Unsupported by Clinical Evidence
The Institute for Clinical and Economic Review (ICER) flagged Humira, Rituxan and Lyrica as the top three most costly U.S. drugs in terms of price-hikes in 2017-2018 that were not supported by new clinical evidence.